{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:28:11Z","timestamp":1788985691768,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s41030-026-00359-w","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:59:15Z","timestamp":1775667555000},"page":"463-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["2025 Annual Review of Pulmonary Arterial Hypertension Clinical Research"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1764-7013","authenticated-orcid":false,"given":"Ilma Alves de Oliveira","family":"Nascimento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-9143","authenticated-orcid":false,"given":"Rog\u00e9rio","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4912-021X","authenticated-orcid":false,"given":"Caio J\u00falio Cesar dos Santos","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"5","key":"359_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296\u2013301.","journal-title":"N Engl J Med"},{"issue":"12","key":"359_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896\u2013903.","journal-title":"N Engl J Med"},{"issue":"5","key":"359_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Gali\u00e8 N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322\u20139.","journal-title":"N Engl J Med"},{"issue":"20","key":"359_CR4","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Gali\u00e8","year":"2005","unstructured":"Gali\u00e8 N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148\u201357.","journal-title":"N Engl J Med"},{"issue":"26","key":"359_CR5","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"issue":"13","key":"359_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"359_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.36660\/abc.20200702","volume":"117","author":"CJ Fernandes","year":"2021","unstructured":"Fernandes CJ, Calderaro D, Assad APL, et al. Atualiza\u00e7\u00e3o no tratamento da hipertens\u00e3o arterial pulmonar. Arq Bras Cardiol. 2021;117(4):750\u201364.","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"359_CR8","doi-asserted-by":"publisher","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","volume":"64","author":"KM Chin","year":"2024","unstructured":"Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325.","journal-title":"Eur Respir J"},{"key":"359_CR9","unstructured":"The World Bank. World Bank country and lending groups: country classification by income. Report No.: 2025. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519, Accessed 20 Jan 2026."},{"issue":"4","key":"359_CR10","doi-asserted-by":"publisher","first-page":"2401095","DOI":"10.1183\/13993003.01095-2024","volume":"64","author":"C Guignabert","year":"2024","unstructured":"Guignabert C, Aman J, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. Eur Respir J. 2024;64(4):2401095.","journal-title":"Eur Respir J"},{"issue":"2","key":"359_CR11","doi-asserted-by":"publisher","first-page":"1022971","DOI":"10.3389\/fddsv.2022.1022971","volume":"15","author":"SJ Cassady","year":"2022","unstructured":"Cassady SJ, Soldin D, Ramani GV. Novel and emerging therapies in pulmonary arterial hypertension. Front Drug Discov. 2022;15(2):1022971.","journal-title":"Front Drug Discov"},{"key":"359_CR12","doi-asserted-by":"crossref","unstructured":"Rasheed A, Aslam S, Sadiq HZ, Ali S, Syed R, Panjiyar BK. New and emerging therapeutic drugs for the treatment of pulmonary arterial hypertension: a systematic review. 2024.  https:\/\/www.cureus.com\/articles\/236294-new-and-emerging-therapeutic-drugs-for-the-treatment-of-pulmonary-arterial-hypertension-a-systematic-review. Accessed 9 Oct 2025.","DOI":"10.7759\/cureus.68117"},{"issue":"4","key":"359_CR13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01205-2024","volume":"64","author":"J Weatherald","year":"2024","unstructured":"Weatherald J, Fleming TR, Wilkins MR, et al. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401205.","journal-title":"Eur Respir J"},{"issue":"3","key":"359_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12271","volume":"13","author":"M Caccamo","year":"2023","unstructured":"Caccamo M, Harrell FE, Hemnes AR. Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension. Pulm Circ. 2023;13(3):e12271.","journal-title":"Pulm Circ"},{"issue":"6","key":"359_CR15","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.3390\/ijms24065850","volume":"24","author":"AJ Shah","year":"2023","unstructured":"Shah AJ, Beckmann T, Vorla M, Kalra DK. New drugs and therapies in pulmonary arterial hypertension. Int J Mol Sci. 2023;24(6):5850.","journal-title":"Int J Mol Sci"},{"key":"359_CR16","doi-asserted-by":"publisher","first-page":"1228148","DOI":"10.3389\/fphar.2023.1228148","volume":"14","author":"ED Namiot","year":"2023","unstructured":"Namiot ED, Smirnovov\u00e1 D, Sokolov AV, Chubarev VN, Tarasov VV, Schi\u00f6th HB. The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs. Front Pharmacol. 2023;14:1228148.","journal-title":"Front Pharmacol"},{"issue":"8","key":"359_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.814222","volume":"24","author":"P Andre","year":"2022","unstructured":"Andre P, Joshi SR, Briscoe SD, Alexander MJ, Li G, Kumar R. Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-\u03b2 superfamily signaling. Front Med. 2022;24(8):814222.","journal-title":"Front Med"},{"issue":"2","key":"359_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02341-2020","volume":"57","author":"C Guignabert","year":"2021","unstructured":"Guignabert C, Humbert M. Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension. Eur Respir J. 2021;57(2):2002341.","journal-title":"Eur Respir J"},{"issue":"543","key":"359_CR19","doi-asserted-by":"publisher","first-page":"eaaz660","DOI":"10.1126\/scitranslmed.aaz5660","volume":"12","author":"LM Yung","year":"2020","unstructured":"Yung LM, Yang P, Joshi S, et al. ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med. 2020;12(543):eaaz660.","journal-title":"Sci Transl Med"},{"key":"359_CR20","volume":"19","author":"G Guglielmi","year":"2025","unstructured":"Guglielmi G, Dimopoulos K, Wort SJ. New therapies in pulmonary arterial hypertension: recent insights. Int J Cardiol Cong Heart Dis. 2025;19:100571.","journal-title":"Int J Cardiol Cong Heart Dis"},{"issue":"9","key":"359_CR21","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1021\/acsptsci.4c00127","volume":"7","author":"YJ Lai","year":"2024","unstructured":"Lai YJ, Yeh YH, Huang YL, et al. Empagliflozin attenuates pulmonary arterial remodeling through peroxisome proliferator-activated receptor gamma activation. ACS Pharmacol Transl Sci. 2024;7(9):2725\u201338.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"359_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.3435","volume":"166","author":"I Lemonjava","year":"2024","unstructured":"Lemonjava I, Gudushauri N, Tskhakaia I, Martinez Manzano JM, Azmaiparashvili Z. Impact of SGLT2 inhibitors on mortality in pulmonary arterial hypertension: exploring the association. Chest. 2024;166(4):A5793.","journal-title":"Chest"},{"issue":"7","key":"359_CR23","doi-asserted-by":"publisher","first-page":"37460","DOI":"10.31083\/RCM37460","volume":"26","author":"S Chen","year":"2025","unstructured":"Chen S, Liang G, Cheang L, Qu Q, Li X. Metabolic alterations associated with right ventricular dysfunction in pulmonary arterial hypertension: the modulatory effects and improvement mechanisms of exercise. Rev Cardiovasc Med. 2025;26(7):37460.","journal-title":"Rev Cardiovasc Med"},{"issue":"10","key":"359_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","volume":"127","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Gali\u00e9 N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension. Circulation. 2013;127(10):1128\u201338.","journal-title":"Circulation"},{"key":"359_CR25","unstructured":"Cooper J. Apollo Therapeutics marks World Pulmonary Hypertension Day with update on the clinical development of APL-9796 (anti-ZIP12 mAb) for the treatment of pulmonary hypertension. 2025. https:\/\/www.apollotx.com\/news\/apollo-therapeutics-marks-world-pulmonary-hypertension-day-with-update-on-the-clinical-development-of-apl-9796-anti-zip12-mab-for-the-treatment-of-pulmonary-hypertension\/. Accessed 8 Jan 2026."},{"issue":"1","key":"359_CR26","first-page":"27","volume":"64","author":"A \u015eengul","year":"2025","unstructured":"\u015eengul A, Okutan O, Alt\u0131nsoy B, Anar C, Yaz\u0131c\u0131 O, Dede F. The effect of artesunate on bleomycin-induced pulmonary fibrosis. Acta Clin Croat. 2025;64(1):27\u201336.","journal-title":"Acta Clin Croat"},{"key":"359_CR27","unstructured":"Pfizer Inc. Pfizer pipeline. 2024. https:\/\/cdn.pfizer.com\/pfizercom\/product-pipeline\/Pipeline_Update_29OCT2024.pdf?referrer=grok.com. Accessed 8 Jan 2026."},{"issue":"11","key":"359_CR28","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1111\/bcp.16167","volume":"90","author":"M Fonseca","year":"2024","unstructured":"Fonseca M, Ribeiro C, Castilla-Fern\u00e1ndez G, et al. Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double-blind, randomized, placebo-controlled study in healthy subjects. Br J Clin Pharmacol. 2024;90(11):2781\u201392.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"359_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ijms25010036","volume":"25","author":"A D\u2019Agostino","year":"2023","unstructured":"D\u2019Agostino A, Lanzafame LG, Buono L, et al. Modulating NO\u2013GC pathway in pulmonary arterial hypertension. Int J Mol Sci. 2023;25(1):36.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"359_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.767002","volume":"12","author":"A Tettey","year":"2021","unstructured":"Tettey A, Jiang Y, Li X, Li Y. Therapy for pulmonary arterial hypertension: glance on nitric oxide pathway. Front Pharmacol. 2021;12(12):767002.","journal-title":"Front Pharmacol"},{"issue":"4","key":"359_CR31","first-page":"1","volume":"10","author":"A Li","year":"2020","unstructured":"Li A, Zhu Z, He Y, et al. DDCI-01, a novel long acting phospdiesterase-5 inhibitor, attenuated monocrotaline-induced pulmonary hypertension in rats. Pulm Circ. 2020;10(4):1\u201310.","journal-title":"Pulm Circ"},{"issue":"4","key":"359_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40262-025-01491-7","volume":"64","author":"Q Li","year":"2025","unstructured":"Li Q, Huang SS, Zhang DC, et al. Evaluation of safety and pharmacokinetics of DDCI-01, a phosphodiesterase type 5 inhibitor, in healthy participants. Clin Pharmacokinet. 2025;64(4):573\u201383.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"359_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894020962960","volume":"10","author":"O Sitbon","year":"2020","unstructured":"Sitbon O, Nikkho S, Benza R, et al. Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulm Circ. 2020;10(4):1\u201311.","journal-title":"Pulm Circ"},{"issue":"9","key":"359_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"359_CR35","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1183\/09031936.00127113","volume":"43","author":"J Yorke","year":"2014","unstructured":"Yorke J, Corris P, Gaine S, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014;43(4):1106\u201313.","journal-title":"Eur Respir J"},{"key":"359_CR36","doi-asserted-by":"crossref","unstructured":"Chin KM, Gomberg-Maitland M, Channick RN, et al. Psychometric validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire. Chest. 2018;154(4):P848\u201361. https:\/\/journal.chestnet.org\/article\/S0012-3692(18)30649-4\/fulltext.","DOI":"10.1016\/j.chest.2018.04.027"},{"issue":"1","key":"359_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11136-005-3513-4","volume":"15","author":"SP McKenna","year":"2006","unstructured":"McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006;15(1):103\u201315.","journal-title":"Qual Life Res"},{"issue":"1","key":"359_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372.","journal-title":"Health Policy"},{"issue":"11","key":"359_CR39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, et al. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol. 2010;63(11):1179\u201394.","journal-title":"J Clin Epidemiol"},{"key":"359_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2023.08.021","volume":"118","author":"M Lichtblau","year":"2023","unstructured":"Lichtblau M, Titz A, Bahrampoori B, Schmiedeskamp M, Ulrich S. What changed after the 2022 guidelines for pulmonary hypertension? Eur J Intern Med. 2023;118:1\u20135.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"359_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/medicina56040167","volume":"56","author":"L Padervinskiene","year":"2020","unstructured":"Padervinskiene L, Hoppenot D, Krivickiene A, et al. Identification of cardiac MRI and bio-marker thresholds for one-year survival in pre-capillary pulmonary hypertension: prospective study. Medicina (Mex). 2020;56(4):167.","journal-title":"Medicina (Mex)"},{"issue":"1","key":"359_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12931-025-03221-w","volume":"26","author":"Z Liu","year":"2025","unstructured":"Liu Z, Bai Z, Chen X, et al. Advances and applications of biosensors in pulmonary hypertension. Respir Res. 2025;26(1):147.","journal-title":"Respir Res"},{"key":"359_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2024.107548","volume":"142","author":"M \u00d8rb\u00e6k Andersen","year":"2024","unstructured":"\u00d8rb\u00e6k Andersen M, Carlsen J. Continuous heart monitoring in patients with pulmonary hypertension smartwatches and direct transmission to their electronic health records: a trial design. Contemp Clin Trials. 2024;142:107548.","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"359_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1177\/1060028020950726","volume":"55","author":"JM Bingham","year":"2021","unstructured":"Bingham JM, Black M, Anderson EJ, et al. Impact of telehealth interventions on medication adherence for patients with Type 2 Diabetes, hypertension, and\/or dyslipidemia: a systematic review. Ann Pharmacother. 2021;55(5):637\u201349.","journal-title":"Ann Pharmacother"},{"key":"359_CR45","unstructured":"Abraham J. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. In: Tietje C, Brouder A, editors. Handbook of transnational economic governance regimes. 2010. https:\/\/brill.com\/view\/book\/edcoll\/9789004181564\/Bej.9789004163300.i-1081_085.xml. Accessed 30 Dec 2025."},{"issue":"1","key":"359_CR46","doi-asserted-by":"publisher","first-page":"1801908","DOI":"10.1183\/13993003.01908-2018","volume":"53","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908.","journal-title":"Eur Respir J"},{"issue":"2","key":"359_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/pedsos.2024-000374","volume":"1","author":"MA Fremed","year":"2025","unstructured":"Fremed MA, Del Mundo RJS, McCown ME, et al. Feasibility, safety, and efficacy of pediatric cardiac telerehabilitation in adolescents with heart disease. Pediatr Open Sci. 2025;1(2):1\u201311.","journal-title":"Pediatr Open Sci"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00359-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:03:24Z","timestamp":1782147804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00359-w","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Caio Julio Cesar dos Santos Fernandes declares no conflicts of interest related to this work. Ilma Alves de Oliveira Nascimento declares no conflicts of interest related to this work. Rogerio Souza is an Editorial Board member of\n                      Pulmonary Therapy\n                      . Rogerio Souza was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is a review article and does not involve human participants or primary data collection; therefore, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}